A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells.
Naghmeh GholipourAnna Ohradanova-RepicGhasem AhangariPublished in: Journal of cellular biochemistry (2018)
In several cancers, microRNA (miRNAs) play vital roles in tumor initiation, drug resistance, and metastasis. The aim of this study was to examine the expression levels of miR-4301 in human breast cancer and investigate whether its potential roles involved targeting Dopamine receptor D2 (DRD2). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was also used to examine the expression levels of miR-4301 in human breast cancer cell lines MDA-MB-231, MCF-7, and SKBR3. In these cell lines, MTT assay, immunofluorescence staining, caspase assay, proliferation assay, and flow cytometry were conducted to explore the potential functions of miR-4301. The effects of modulating miR-4301 on transcription levels of DRD2 were subsequently confirmed via qRT-PCR. miR-4301 expression levels were significantly decreased in human breast cancer specimens and cell lines (P < 0.05). Transfection of miR-4301 in breast cancer cells suppressed cell proliferation and induced apoptosis. Expression analysis indicated that miR-4301 was inversely correlated with DRD2 expression in breast cancer specimens. qRT-PCR showed that miR-4301 negatively regulated DRD2 expression. Downregulation of DRD2 expression in MDA-MB-231, MCF-7, and SKBR3 cells suppressed cell proliferation and promoted apoptosis.
Keyphrases
- cell proliferation
- poor prognosis
- long non coding rna
- breast cancer cells
- induced apoptosis
- long noncoding rna
- cell cycle
- endothelial cells
- binding protein
- endoplasmic reticulum stress
- pi k akt
- cell cycle arrest
- oxidative stress
- cell death
- induced pluripotent stem cells
- transcription factor
- drug delivery
- high throughput
- mass spectrometry
- metabolic syndrome
- single cell
- risk assessment
- prefrontal cortex
- human health
- ultrasound guided
- breast cancer risk